Envista (NYSE:NVST) Given New $18.00 Price Target at Evercore ISI

Envista (NYSE:NVST) had its price target reduced by Evercore ISI from $19.00 to $18.00 in a report published on Thursday, Benzinga reports. They currently have an outperform rating on the stock.

A number of other research firms have also recently weighed in on NVST. Robert W. Baird dropped their target price on shares of Envista from $19.00 to $17.00 and set a neutral rating on the stock in a research note on Monday, July 22nd. Morgan Stanley lowered Envista from an overweight rating to an equal weight rating and dropped their price objective for the company from $33.00 to $21.00 in a research note on Friday, April 26th. Piper Sandler decreased their price target on shares of Envista from $18.00 to $16.00 and set a neutral rating on the stock in a report on Tuesday, July 30th. JPMorgan Chase & Co. lowered Envista from an overweight rating to a neutral rating and reduced their price objective for the company from $23.00 to $16.00 in a research report on Thursday. Finally, Stifel Nicolaus lowered their price target on shares of Envista from $20.00 to $18.00 and set a buy rating for the company in a research note on Tuesday, July 30th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $19.14.

Envista Trading Down 1.9 %

Shares of NYSE:NVST traded down $0.32 during midday trading on Thursday, reaching $16.18. The company’s stock had a trading volume of 4,446,997 shares, compared to its average volume of 2,442,982. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of -22.94, a PEG ratio of 14.74 and a beta of 1.31. The firm has a 50 day moving average price of $16.89 and a two-hundred day moving average price of $19.54. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.93 and a current ratio of 2.27. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $33.84.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.16). Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business had revenue of $633.10 million for the quarter, compared to the consensus estimate of $646.88 million. During the same quarter last year, the firm posted $0.43 EPS. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. As a group, analysts forecast that Envista will post 1.15 earnings per share for the current year.

Hedge Funds Weigh In On Envista

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jupiter Asset Management Ltd. purchased a new stake in shares of Envista in the 2nd quarter worth about $69,534,000. Nuance Investments LLC grew its holdings in Envista by 953.8% in the fourth quarter. Nuance Investments LLC now owns 3,931,054 shares of the company’s stock worth $94,581,000 after purchasing an additional 3,558,031 shares during the period. Swedbank AB bought a new position in shares of Envista during the first quarter valued at approximately $53,412,000. River Road Asset Management LLC purchased a new position in shares of Envista during the fourth quarter valued at approximately $54,931,000. Finally, Franklin Resources Inc. boosted its position in shares of Envista by 65.3% in the 4th quarter. Franklin Resources Inc. now owns 5,262,092 shares of the company’s stock worth $126,606,000 after purchasing an additional 2,077,786 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.